Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
off-target toxicity
Description:
Harmful effects caused by a drug or biological treatment acting on unintended cells, tissues, or molecular targets.
Related topics:
CAR-T cell therapy research (15%),
Nanoparticle-Based Drug Delivery (11%)
OpenAlex ID:
keywords/off-target-toxicity
Targeting apoptosis in cancer therapy
2020
·
Benedito A. Carneiro
, Wafik S. El-Deiry
·
Nature Reviews Clinical Oncology
·
2,826
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
2013
·
Gerald P. Linette
, Edward A. Stadtmauer
, et al.
·
Blood
·
1,293
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
2009
·
Aimee L. Jackson
, Peter S. Linsley
·
Nature Reviews Drug Discovery
·
1,272
Nanomedicine in cancer therapy
2023
·
Dahua Fan
, Yongkai Cao
, et al.
·
Signal Transduction and Targeted Therapy
·
1,072
PDF
The antifungal pipeline: a reality check
2017
·
John R. Perfect
·
Nature Reviews Drug Discovery
·
961
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
2012
·
Christopher C Kloss
, Maud Condomines
, et al.
·
Nature Biotechnology
·
912
Gold nanoparticle‐mediated photothermal therapy: applications and opportunities for multimodal cancer treatment
2017
·
Rachel S. Riley
, Emily S. Day
·
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
·
898
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
2017
·
Carlo Rinaldi
, Matthew J. A. Wood
·
Nature Reviews Neurology
·
880
PDF
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
2019
·
Ann Lin
, Christopher J. Giuliano
, et al.
·
Science Translational Medicine
·
807
PDF
Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells
2013
·
Brian J. Cameron
, Andrew B. Gerry
, et al.
·
Science Translational Medicine
·
749
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
2015
·
Madduri Srinivasarao
, Chris V. Galliford
, et al.
·
Nature Reviews Drug Discovery
·
746
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
2023
·
Onyinyechi Obidiro
, Gantumur Battogtokh
, et al.
·
Pharmaceutics
·
643
PDF
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
2015
·
Xiaojun Liu
, Shuguang Jiang
, et al.
·
Cancer Research
·
621
HDL, ABC Transporters, and Cholesterol Efflux: Implications for the Treatment of Atherosclerosis
2008
·
Alan R. Tall
, Laurent Yvan-Charvet
, et al.
·
Cell Metabolism
·
611
PDF
Recent advances in polymeric micelles for anti-cancer drug delivery
2015
·
Swati Biswas
, Preeti Kumari
, et al.
·
European Journal of Pharmaceutical Sciences
·
511
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
2012
·
Elena Provasi
, Pietro Genovese
, et al.
·
Nature Medicine
·
488
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
2023
·
Toan D. Nguyen
, Brandon M. Bordeau
, et al.
·
Cancers
·
483
PDF
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
2019
·
Michael J Birrer
, Kathleen N Moore
, et al.
·
JNCI Journal of the National Cancer Institute
·
475
Antibody–drug conjugates: Recent advances in linker chemistry
2021
·
Zheng Su
, Dian Xiao
, et al.
·
Acta Pharmaceutica Sinica B
·
447
PDF
Covalent inhibitors: a rational approach to drug discovery
2020
·
Fandi Sutanto
, Markella Konstantinidou
, et al.
·
RSC Medicinal Chemistry
·
430
PDF
Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development
2010
·
F. Peter Guengerich
·
Drug Metabolism and Pharmacokinetics
·
429
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
2018
·
Remy Thomas
, Ghaneya Al-Khadairi
, et al.
·
Frontiers in Immunology
·
422
PDF
P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
2013
·
Ziyad Binkhathlan
, Afsaneh Lavasanifar
·
Current Cancer Drug Targets
·
419
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
2008
·
M Vogler
, D Dinsdale
, et al.
·
Cell Death and Differentiation
·
400
PDF
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
2011
·
Thomas Force
, Kyle L. Kolaja
·
Nature Reviews Drug Discovery
·
395
Show more works
View as search
Works count:
2,522
Citation count:
68,060
Year
Topic
Type